August 2012
-
CDMO Particle Sciences is now registered with the US Drug Enforcement Administration (DEA) as a manufacturer of Schedule I substances, which means that the company can now provide development and manufacturing services for pharmaceutical cannabinoid… Read more . . .
-
Proveris Scientific has announced the availability of new testing services that “support the FDA’s newly released draft guidance on beclomethasone dipropionate that promotes alternate in-vitro studies in lieu of clinical endpoint.” According to Proveris, the… Read more . . .
-
Insmed Incorporated said that a just-closed public stock offering generated net proceeds of about $235.5 million that will be used for continuing commercialization of Arikayce amikacin liposome inhalation suspension (ALIS). The offering of 9,615,385 shares of… Read more . . .
-
Inhalation Sciences (ISAB) has announced that it will divest 40,000 shares of its subsidiary Ziccum AB in order to finance a study to validate its PreciseInhale dosing system for clinical use. The company said that… Read more . . .
-
Vectura Group and Sosei Group each said that they are owed $2.5 million milestone payments from Novartis after the EU accepted Novartis’s MAA for its QVM149 indacaterol/glycopyrronium/mometasone furoate DPI for the treatment of asthma that… Read more . . .
-
KAER Biotherapeutics gets SBIR grant for development of aerosol therapy for RDS in premature infants
KAER Biotherapeutics has received a $300,000 Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute of the National Institutes of Health for preclinical development of its SUPRAER aerosol platform for… Read more . . .
-
Led by inhaler device platform designer and supplier Merxin and by Nanopharm, a CRO specializing in inhaled and nasal drugs, a group of companies that offer products and services for OINDP development has come together… Read more . . .
-
The FDA has approved an ANDA for Akorn’s generic azelastine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis in patients 5 years old and older and for vasomotor rhinitis in patients 12 and… Read more . . .
-
A study published May 19, 2019 in the New England Journal of Medicine found that the Symbicort Turbuhaler budesonide/formoterol DPI demonstrated a greater than 50% reduction in the risk of asthma exacerbations in mild asthma… Read more . . .
-
Respivant Sciences has announced dosing of the first patient in the Phase 2b SCENIC trial of its RVT-1601 cromolyn sodium inhalation solution for the treatment of cough in idiopathic pulmonary fibrosis (IPF) patients. Respivant was… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.